Vivanza Biosciences shareholders approve borrowing limit increase at AGM

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Vivanza Biosciences shareholders approved borrowing limit increase under Section 180(1)(C)
  • All ordinary and special resolutions passed at the 44th AGM held on September 11, 2026
  • Company issued corrigendum confirming NSDL as e-voting provider, not CDSL
  • No changes to voting results or resolution outcomes despite provider name correction
powered bylight_fuzz_icon
50671340

*this image is generated using AI for illustrative purposes only.

Vivanza Biosciences held its 44th Annual General Meeting on September 11, 2026. Shareholders approved key special resolutions, including an increase in borrowing limits under Section 180(1)(C) of the Companies Act, 2013.

The meeting was conducted via video conferencing in compliance with Ministry of Corporate Affairs circulars. The Company Secretary confirmed that the requisite quorum was present throughout the proceedings.

Key Resolutions Approved

Shareholders voted on several ordinary and special business items. The primary focus included governance updates and financial authority expansions.

Item Type Resolution Description Status
Ordinary Adoption of FY26 audited standalone and consolidated financial statements Passed
Ordinary Re-appointment of Mr. Jayendra Mehta as Director Passed
Special Regularization of Mr. H.A. Parikh as Non-Executive Non-Independent Director Passed
Special Approval of material Related Party Transactions for FY27 Passed
Special Adoption of new Memorandum of Association Passed
Special Adoption of new Articles of Association Passed
Special Increase in Borrowing Limits under Section 180(1)(C) Passed
Special Approval for Investments, Loans, and Guarantees under Section 186 Passed
Special Approval for loans/guarantees to interested Directors under Section 185 Passed

Management Commentary

Mr. Jainil Bhatt, Chief Financial Officer, apprised members of the company’s financial performance and future prospects. No questions or queries were raised by shareholders during the session.

The Chairman and Managing Director, Mr. Mehta J.A., presided over the meeting. Other attendees included Independent Directors Mr. Hitesh Rijwani and Ms. Reena Kumari, along with Statutory Auditor Mr. Shivam Soni and Secretarial Auditor Mr. Chintan Patel.

Voting Process and Corrigendum

Remote e-voting was open from September 8 to September 10, 2026. Members could also vote electronically during the AGM. Mr. Chintan K. Patel served as the Scrutinizer for the voting process. The combined results will be disseminated to stock exchanges within 48 hours of the meeting's conclusion.

The company issued a corrigendum on September 12, 2026, clarifying that the e-voting service provider was National Securities Depository Limited (NSDL), not Central Depository Services (India) Limited (CDSL) as erroneously stated in the initial report. The voting percentages and resolution outcomes remain unchanged.

Historical Stock Returns for Vivanza Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.53%+8.62%+0.53%-6.44%-6.90%0.0%

How will the increased borrowing limits under Section 180(1)(C) influence Vivanza Biosciences' capital allocation strategy for upcoming R&D or expansion projects?

What specific related party transactions were approved for FY27, and how might they impact the company's operational independence or cost structure?

Does the regularization of Mr. H.A. Parikh as a Non-Executive Non-Independent Director signal a shift in corporate governance dynamics or board composition?

Vivanza Biosciences schedules 44th AGM for September 11, 2026

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights

Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting (AGM) for Friday, September 11, 2026, at 3:30 pm via VC/OAVM. The primary agenda includes adopting audited financials for FY26, which show a turnaround to a net profit of ₹37.50 lakh on revenue of ₹11,234.04 lakh. Shareholders will also vote on special resolutions for borrowing limits up to ₹100 crore and board reappointments.

powered bylight_fuzz_icon
48511431

*this image is generated using AI for illustrative purposes only.

Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting (AGM) for Friday, September 11, 2026, at 3:30 pm. The meeting will be conducted through Video Conference or Other Audio-Visual Means (VC/OAVM), with the deemed venue fixed at the company’s registered office in Ahmedabad. This follows a board meeting held on August 17, 2026, where directors approved the convening of the AGM and proposed amendments to constitutional documents.

Financial Results for FY26

The primary ordinary business item involves the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026. During FY26, the company reported a significant turnaround in profitability. Standalone revenue from operations rose to ₹11,234.04 lakh, up from ₹297.74 lakh in the previous year. The company posted a net profit of ₹37.50 lakh after tax, compared to a net loss of ₹69.51 lakh in FY25. Consolidated revenue stood at ₹11,602.21 lakh, with consolidated profit after tax at ₹39.44 lakh.

Metric Standalone FY26 Standalone FY25 Consolidated FY26 Consolidated FY25
Total Revenue (₹ lakh) 11,234.04 297.74 11,602.21 748.48
Profit Before Tax (₹ lakh) 51.79 (69.36) 54.37 (66.57)
Profit After Tax (₹ lakh) 37.50 (69.51) 39.44 (67.41)

The Board did not recommend any dividend for the year under review. Reserves and surplus stood at ₹39.54 lakh as of March 31, 2026, compared to ₹2.04 lakh at the beginning of the year.

Board Appointments and Reappointments

Shareholders will consider the reappointment of Mr. Jayendra A. Mehta as Managing Director, who retires by rotation at this AGM and is eligible for reappointment. Additionally, the meeting will approve the regularization of Mr. H.A. Parikh as a Non-Executive Non-Independent Director. Mr. Parikh was initially appointed as an Additional Director with effect from June 18, 2026, and holds office until this AGM.

Other board changes disclosed include the appointment of Mr. Sarang B. Pathak as a Non-Executive Non-Independent Director effective August 30, 2025, and Mr. Hitesh Rijwani as an Independent Director effective May 12, 2025. Ms. Rina Kumari continues as an Independent Director.

Special Resolutions and Corporate Governance

The AGM will seek shareholder approval for several special resolutions:

  • Related Party Transactions: Approval for material related party transactions during FY27, with an aggregate limit of up to ₹100 crore.
  • Borrowing Limits: Increase in borrowing limits under Section 180(1)(c) of the Companies Act, 2013, allowing the board to borrow sums exceeding the aggregate of paid-up share capital, free reserves, and securities premium, up to ₹100 crore.
  • Investments and Guarantees: Approval under Section 186 for investments, loans, guarantees, or securities up to ₹50 crore.
  • Loans to Interested Entities: Approval under Section 185 for loans or financial assistance to entities in which directors are interested, up to ₹50 crore.
  • Constitutional Documents: Adoption of new Memorandum of Association (MoA) and Articles of Association (AoA) aligned with the Companies Act, 2013.

E-Voting and Meeting Logistics

The cut-off date for determining member eligibility to attend and vote is September 4, 2026. Remote e-voting will be available from September 8, 2026, at 9:00 am to September 10, 2026, at 5:00 pm, through the National Securities Depository Limited (NSDL) e-voting system. Mr. Chintan K. Patel, a practicing company secretary, has been appointed as the scrutinizer to oversee the e-voting process. Participation in the VC/OAVM meeting is limited to 1,000 members on a first-come, first-served basis, excluding large shareholders holding 2% or more, promoters, institutional investors, and key managerial personnel.

Historical Stock Returns for Vivanza Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
+0.53%+8.62%+0.53%-6.44%-6.90%0.0%

What specific strategic initiatives or product launches drove the massive revenue surge from ₹297.74 lakh to ₹11,234.04 lakh in FY26?

How does the board plan to utilize the newly approved ₹100 crore borrowing limit to fuel future growth or manage debt obligations?

Given the significant increase in borrowing and investment powers, what are the company's stated plans for capital allocation in FY27?

More News on Vivanza Biosciences

1 Year Returns:-6.90%